Abbott Laboratories (NYSE:ABT) Stock Price Target Raised at Robert W. Baird

Key Points

• Robert W. Baird raised Abbott’s price target from $121 to $123 and maintained an “outperform” rating, implying approximately 22% upside. Analysts overall rate the stock “Moderate Buy,” with an average target of $118.60.
• Abbott’s third-quarter results showed revenue rising 14.5% year over year to $13.01 billion, while adjusted EPS of $1.42 matched consensus estimates. However, the company lowered its 2026 sales-growth outlook because of weakness in medical devices.
• Abbott plans to spin off its roughly $8.5 billion nutrition business—including Ensure and Similac—into a separate public company by the end of 2027, a move that could sharpen strategic focus but carries execution and structural risks.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its price objective lifted by stock analysts at Robert W. Baird from $121.00 to $123.00 in a report issued on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the healthcare product maker's stock. Robert W. Baird's target price indicates a potential upside of 22.28% from the stock's current price.

Other equities research analysts have also issued reports about the company. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a research note on Thursday, August 13th. Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. Royal Bank Of Canada reissued an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, TD Cowen reaffirmed a "buy" rating and set a $135.00 price target on shares of Abbott Laboratories in a report on Friday, October 16th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $118.60.

Abbott Laboratories Price Performance

NYSE ABT opened at $100.59 on Thursday. The stock has a market capitalization of $174.06 billion, a price-to-earnings ratio of 32.55, a PEG ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business's fifty day moving average price is $105.47 and its 200-day moving average price is $98.28.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts' consensus estimates of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analysts' expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. Abbott Laboratories's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.30 earnings per share. On average, equities analysts predict that Abbott Laboratories will post 5.53 earnings per share for the current year.

Institutional Investors Weigh In On Abbott Laboratories

A number of hedge funds have recently bought and sold shares of the business. Ledyard National Bank lifted its stake in shares of Abbott Laboratories by 6.4% in the third quarter. Ledyard National Bank now owns 15,237 shares of the healthcare product maker's stock valued at $1,506,000 after buying an additional 913 shares during the period. Culbertson A N & Co. Inc. raised its holdings in Abbott Laboratories by 0.3% during the 3rd quarter. Culbertson A N & Co. Inc. now owns 90,195 shares of the healthcare product maker's stock worth $8,914,000 after purchasing an additional 270 shares during the last quarter. NBT Bank N.A. bought a new position in Abbott Laboratories in the third quarter valued at approximately $9,060,000. Root Financial Partners LLC boosted its position in shares of Abbott Laboratories by 93.7% in the 3rd quarter. Root Financial Partners LLC now owns 7,430 shares of the healthcare product maker's stock worth $734,000 after purchasing an additional 3,594 shares during the last quarter. Finally, Precedent Wealth Partners LLC grew its stake in shares of Abbott Laboratories by 10.7% during the third quarter. Precedent Wealth Partners LLC now owns 33,354 shares of the healthcare product maker's stock worth $3,296,000 after purchasing an additional 3,234 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, matching the consensus estimate, while revenue increased 14.5% year over year to $13.01 billion, slightly above the $12.99 billion forecast. Comparable sales grew 7%, and the company reaffirmed its full-year adjusted EPS guidance. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Management announced a tax-free spin-off of its global Nutrition business, which includes brands such as Ensure, Similac, PediaSure, Glucerna and Pedialyte. Abbott expects the transaction to create two more focused companies, potentially accelerating Abbott’s sales growth and expanding its margin profile. Completion is targeted for the end of 2027. Abbott Nutrition Spin-Off Announcement
• Positive Sentiment: New product approvals and the European CE Mark for Abbott’s Cologuard Plus colorectal cancer test broaden the company’s diagnostics opportunity and could support longer-term growth. Abbott Secures Europe CE Mark for Colorectal Cancer Test
• Neutral Sentiment: The planned separation involves a nutrition operation generating approximately $8.5 billion in annual sales. While it may unlock value, investors will need to assess the eventual ownership structure, costs, tax implications and execution risks before determining whether the move improves shareholder returns. Abbott to Carve Out Nutrition Business
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing weakness in medical devices. That guidance reduction overshadowed revenue growth and the reaffirmed EPS outlook, raising concerns about near-term demand and the company’s valuation. Abbott Lowers 2026 Sales Growth Forecast
• Negative Sentiment: Although adjusted EPS met the broad consensus, it was below the $1.43 estimate tracked by Zacks. The modest earnings shortfall, combined with the lower sales outlook, contributed to the stock’s decline despite higher revenue and expanding margins. Abbott Misses Q3 Earnings Estimates

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.